ResearcherTufts UniversityNo recent work listed

Dimitra Grapsa

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5083015425. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper

Papers 2

The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. First author DOI 10.1080/14737140.2016.1192471 ↗
Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? Co-author DOI 10.4251/wjgo.v7.i10.172 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Muhammad Wasif Saif · 2 shared papers, 2015–2016 · strength 0.17
- Paper The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer fo… DOI 10.1080/14737140.2016.1192471 ↗
- Paper Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? DOI 10.4251/wjgo.v7.i10.172 ↗
Kostas Syrigos · 1 shared paper, 2016 · strength 0.08
- Paper The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer fo… DOI 10.1080/14737140.2016.1192471 ↗
Frank Charles Passero · 1 shared paper, 2016 · strength 0.08
- Paper The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer fo… DOI 10.1080/14737140.2016.1192471 ↗
Konstantinos Nikolaos Syrigos · 1 shared paper, 2015 · strength 0.08
- Paper Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? DOI 10.4251/wjgo.v7.i10.172 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.